Wipfli Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wipfli Financial Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$108K	Buy	+812	New	+$123K	0.01%	692

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wipfli Financial Advisors's JAZZ Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q3 2022: 812 shares worth $108K. The stake represents 0.01% of the portfolio and ranks #692 among its holdings.

468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

Wipfli Financial Advisors held 812 shares of Jazz Pharmaceuticals worth $108K as of Q3 2022.
Jazz Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Jazz Pharmaceuticals made up 0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #692 holding.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.